Replimune Group (NASDAQ:REPL) Upgraded by JPMorgan Chase & Co. to Neutral Rating

Replimune Group (NASDAQ:REPL) was upgraded by equities research analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a research report issued on Friday, Marketbeat Ratings reports. The brokerage presently has a $8.00 target price on the stock. JPMorgan Chase & Co.‘s target price suggests a potential downside of 7.48% from the company’s previous close.

Several other analysts have also recently commented on the company. Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Piper Sandler cut Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price on the stock. in a report on Friday, April 10th. Jefferies Financial Group restated a “hold” rating and set a $2.00 target price (down from $13.00) on shares of Replimune Group in a report on Monday, April 13th. Cantor Fitzgerald cut Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. Finally, Weiss Ratings upgraded Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. Seven investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $4.38.

Replimune Group Price Performance

Replimune Group stock traded up $3.97 during mid-day trading on Friday, hitting $8.65. 44,434,599 shares of the company were exchanged, compared to its average volume of 4,699,200. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33. The business has a fifty day moving average of $4.84 and a 200 day moving average of $7.25. Replimune Group has a 1-year low of $1.50 and a 1-year high of $13.24. The company has a market capitalization of $713.98 million, a PE ratio of -2.52 and a beta of 0.12.

Insider Activity at Replimune Group

In related news, insider Christopher Sarchi sold 6,500 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total value of $52,065.00. Following the completion of the sale, the insider owned 151,588 shares in the company, valued at $1,214,219.88. This trade represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by company insiders.

Institutional Trading of Replimune Group

Several institutional investors and hedge funds have recently modified their holdings of REPL. International Assets Investment Management LLC purchased a new stake in shares of Replimune Group during the fourth quarter worth about $29,000. Russell Investments Group Ltd. grew its holdings in Replimune Group by 3,638.9% in the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after purchasing an additional 7,569 shares during the period. CWM LLC increased its stake in Replimune Group by 248.6% during the fourth quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after acquiring an additional 2,886 shares during the last quarter. Essential Partners LLC raised its holdings in shares of Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock worth $43,000 after purchasing an additional 5,624 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in shares of Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after purchasing an additional 6,873 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.